What is this?
Compendial testing applies official monograph or general-chapter methods to pharmaceutical raw materials and finished products, often supporting CoA issuance and regulatory submissions.
Start with the regulated decision
Use USP/NF, EP, JP, BP, AOAC, ACS, and other monograph methods for raw-material and finished-product testing.
For cGMP work, method choice has to follow the quality attribute, sample matrix, method status, documentation need, and regulatory decision. The testing plan should connect method development, validation, method transfer, release testing, CoA support, and documentation requirements rather than treating each instrument run as an isolated activity.
Overview of cGMP Compendial Testing Services
When is it used?
Use it for USP/NF, EP, JP, BP, AOAC, ACS, or related testing such as ID, residual solvents, melting range, loss on drying, dissolution, HPLC/GC, IR, metals, dosage uniformity, Karl Fischer, pH, and wet-chemistry tests.
What are limitations?
A monograph method may still require verification, suitability for the actual matrix, system suitability, correct reference standards, and careful interpretation where the material or product differs from the monograph assumptions.
What sample amounts are needed?
Sample amounts follow the monograph, test panel, replicate needs, retains, and any verification or investigation plan.
What techniques compete with it?
Validated non-compendial methods, chromatographic assays, spectroscopy, XRPD, NMR, MS, particle methods, thermal analysis, KF, and elemental analysis may be needed if the compendial method does not answer the quality question.
What does FDA care about?
FDA cares that the method is scientifically justified, specific for the intended attribute in the real matrix, controlled under the quality system, validated or verified where appropriate, data-integrity compliant, and lifecycle managed.
What are common mistakes?
Common mistakes include using exploratory data as release evidence, validating the wrong matrix, ignoring sample preparation, under-documenting controls, relying on one technique when orthogonal evidence is needed, or failing to define the decision before testing.
What is Triclinic's experience with this technique
Triclinic applies compendial testing in real-world release, stability, raw-material, and regulatory-support programs where methods must be executed under controlled procedures and defensible documentation. Typical use includes USP, EP, or other monograph-based testing, method verification where required, specification support, CoA-ready reporting, and investigations when a compendial result does not align with material history or expected performance.
What changes when the work is cGMP?
Exploratory data can help choose a method, but release or filing-support data require controlled execution. The method must be suitable for the matrix, the quality attribute must be defined, reference standards and controls must be appropriate, and the report or CoA must say only what the data support.
| cGMP concern | Why it matters | Practical control |
|---|---|---|
| Method status | Exploratory, verified compendial, validated custom, and transferred methods have different evidence requirements. | Define status before testing and document any development, verification, validation, or transfer work. |
| Sample matrix | Specificity can fail in real drug product, excipient, talc, low-dose, or complex solid mixtures. | Use representative material, placebo/matrix controls, spike studies, or orthogonal methods where needed. |
| Data integrity | Release or stability results must survive QA review, audit, and regulatory scrutiny. | Use controlled records, system suitability, analyst review, deviations/OOS process, and traceable calculations. |
Specific instruments and capabilities for cGMP Compendial Testing
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this cGMP service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| HPLC / UPLC platforms | Agilent 1100 and Agilent 1260 Infinity II systems with Chromeleon 7.2 software; diode-array, refractive-index, and light-scattering detectors | Assay, impurity, potency, purity, method development, transfer, validation, and compendial testing workflows. |
| Dissolution testing | VanKel VF750D dissolution platform with UV/VIS or HPLC detection | USP <711>-style dissolution profiles and release-support testing where the monograph or method requires dissolution evidence. |
| Disintegration testing | Testerion DT2 | Tablet and hard-gelatin capsule disintegration testing under standardized conditions. |
| Karl Fischer water determination | Mettler Toledo V20 and C20 systems with coulometric, volumetric, and oven KF configurations | Water-content methods, low-RH handling support, and specification/stability investigations. |
| ICP-MS trace-element platform | Thermo Fisher Scientific iCAP RQ ICP-MS, single-quadrupole ICP-MS | Trace and ultra-trace elemental analysis, inorganic impurity testing, USP <232>/<233> and ICH Q3D support, and multi-element method development/validation. |
| Powder X-ray diffraction | Rigaku SmartLab diffractometers with Cu source; 1D/2D capability; reflection and transmission geometries; HyPix-3000 photon-counting detector on the 2D system | Phase ID, quantitative phase analysis, crystallinity, solid-form control, and cGMP/non-GMP XRPD method support. |
| 400 MHz NMR platform | Bruker 400 MHz UltraShield Avance AVII | cGMP and non-cGMP liquid-state NMR and non-GMP solid-state NMR for structure confirmation, qNMR, impurity support, and reference-standard characterization. |
| NMR software and multinuclear probes | Bruker TopSpin 3.2; broadband probes supporting 1H, 13C, 31P, 19F, 15N, and other nuclei | Acquisition, processing, integration, spectral comparison, qNMR calculations, structural interpretation, and multinuclear experiments for drug substances, drug products, impurities, salts, excipients, and formulated systems. |
| Particle-size analysis | Malvern Mastersizer 3000 v.3.70 with Malvern Access Configurator v.2.20 | Laser-diffraction particle-size analysis; dry range 0.1-3500 um and wet range 0.01-1400 um; cGMP and non-GMP method development, verification, transfer, validation, and release-testing support. |
| Thermogravimetric analysis | TA Instruments Q50 and TA Discovery 5500 TGA systems | Mass-loss, moisture/volatile content, decomposition, oxidative stability, residue/composition analysis, and cGMP thermal-method support. |
| Differential scanning calorimetry | TA Instruments Q2000 and Q2500 Discovery DSC systems | Melting, crystallization, glass transition, heat capacity, compatibility, transition enthalpy, and modulated DSC support for cGMP and non-GMP workflows. |
| Dispersive Raman microscopy | Renishaw inVia Raman microscope with DMLM Leica microscope, 785 nm laser, and CCD detector | Chemical imaging, confocal microsampling, polymorph discrimination, component mapping, and non-destructive molecular fingerprinting. |
| FT-Raman and FT-IR spectroscopy | Thermo NXT FT-Raman module interfaced to Nicolet 6700 FT-IR spectrometer; Thermo iS50 Model 60825 and Nicolet 6700 FT-IR systems; OMNIC v.9.7.46 software | Raman and IR identification, ATR/diffuse reflectance/transmission sampling, library matching, functional-group identification, and gas-cell/TGA-IR support. |
| Infrared imaging | Thermo iN10 MX with Picta 1.5.141 software | IR chemical imaging, ATR/reflection/transmission sampling, microsampling, real-time particle identification, and distribution mapping. |
| Optical, digital, and polarized-light microscopy | Leica M80 stereo microscope; Leica DM2500P compound/polarizing microscope; Keyence VHX-2000E digital microscope; Pax-it2! v.1.4.3 software | Still/dynamic image capture, birefringence, morphology, particle habit, topography, and visual documentation for cGMP morphology and compendial-support workflows. |
| SEM/EDX | Thermo Phenom XL with fully integrated EDX and BSE detector; FEI Quanta 3D FEG with high-vacuum, low-vacuum, and cryo capability | High-resolution morphology, particle/contaminant examination, BSE contrast, elemental analysis, and cryogenic or low-vacuum imaging workflows. |
Compendial Method Verification and cGMP Release Readiness
This example shows how compendial testing becomes more than execution of a monograph when the data are used for release, stability, CoA issuance, or regulatory support. For cGMP compendial programs, USP/NF, EP, JP, BP, AOAC, ACS, and other pharmacopoeial methods may apply to APIs, excipients, intermediates, and finished products, with method verification, alternative method development, validation, and documentation handled according to the intended quality decision.
| Compendial or cGMP decision point | Practical implication |
|---|---|
| Official monograph or general chapter | Confirm that the method, matrix, reference standards, system suitability, and sample preparation are suitable before relying on the result. |
| Alternative or non-compendial method | Define whether method development, verification, validation, or transfer is required before the data can support a regulated decision. |
| CoA or release support | Align acceptance criteria, method status, analyst training, deviation handling, and report language with the intended quality use. |
| Supplier or raw-material qualification | Use compendial results together with identity, impurity, physical-property, and lot-history evidence when the material is critical to product quality. |
Technical Resources and Publications
These examples cite Triclinic source documents, regulatory guidances, or literature relevant to this cGMP service. Download buttons are positioned at the bottom-left of each example.
ICH Q2(R2) Validation of Analytical Procedures and ICH Q14 Analytical Procedure Development
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: These harmonized guidances describe validation and development principles for analytical procedures used to assess drug-substance and drug-product quality. They anchor expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence in cGMP work.
Related cGMP services
NMR
Use cGMP NMR for identity, purity, qNMR, reference-material verification, method development, validation, and release testing.
View serviceXRPD
Use cGMP XRPD for solid-form identification, polymorph or phase quantitation, crystallinity, method validation, release, and stability support.
View serviceParticle Size Analysis
Develop, validate, verify, and transfer wet or dry particle-size methods for release specifications and quality decisions.
View serviceThermal Analysis (TGA/DSC)
Use cGMP DSC and TGA to evaluate melting, desolvation, dehydration, glass transitions, degradation, and thermal material control.
View serviceRaman / FTIR
Use cGMP Raman and FTIR for raw-material ID, solid-form differentiation, mapping, contaminant ID, and validated spectroscopic methods.
View serviceMorphology
Use cGMP microscopy and particle morphology evidence for identification, particle shape, foreign-material work, and regulated investigations.
View serviceFrequently Asked Questions about cGMP Compendial Testing
When should cGMP Compendial Testing be run under cGMP?
Run the work under cGMP when the result will support release, stability, regulatory documentation, method validation or transfer, CoA issuance, or a quality investigation rather than exploratory screening only.
How much material should be submitted?
Material requirements depend on method, matrix, replicate design, standards, destructive testing, retain needs, and whether method development, validation, transfer, or release testing is required. Confirm exact amounts before shipment.
Can Triclinic help choose the method?
Yes. The project should be scoped from the quality attribute, sample matrix, method status, and regulatory decision before selecting a technique or validation plan.
What makes the result defensible?
Defensible cGMP results require appropriate method status, sample traceability, reference standards, controls, system suitability, analyst training, data review, and clear reporting of limitations.
Do you develop, validate, and transfer methods?
Yes. Triclinic develops, validates, verifies, and transfers methods when a compendial method must be implemented for a specific matrix or when a noncompendial alternative is needed. Work can include method verification, suitability assessment, supplemental validation, sample preparation controls, system suitability, acceptance criteria, documentation, and transfer support for USP, EP, JP, BP, or client-specific testing programs.
Does a compendial method require verification?
Often, yes. A compendial procedure should be demonstrated as suitable for the specific article, matrix, laboratory, instrument, and intended use. The required verification scope depends on the method and the risk of the result.
Discuss cGMP compendial testing with us!
We'd be happy to discuss compendial testing approaches for USP/NF, EP, JP, BP, AOAC, ACS, or client-specific methods, including method verification, release testing, CoA support, stability, raw-material qualification, and regulatory documentation. Click the button to get started...